Skip navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

URL of this page: https://medlineplus.gov/druginfo/natural/891.html

Bifidobacterium animalis subsp. lactis

What is it?

Bifidobacterium animalis subsp. lactis (B. lactis) is a type of probiotic ("good" bacteria) that lives in the intestines. It produces lactic and acetic acid.

"Good" bacteria such as B. lactis can help break down food, absorb nutrients, and fight off "bad" organisms that might cause diseases. B. lactis is a subspecies of B. animalis. It's found in the human gut and used in probiotic supplements.

People use B. lactis for excessive crying in infants (colic), constipation, irritable bowel syndrome (IBS), and respiratory tract infections. It is also used for dental cavities, hay fever, diarrhea, and many other conditions, but there is no good scientific evidence to support many of these uses. There is also no good evidence to support using B. lactis for COVID-19.

Bifidobacterium animalis subsp. lactis is sometimes listed as Bifidobacterium lactis (or B. lactis) on product labels. Don't confuse B. lactis with other probiotics, or with fermented food products such as fermented milk, kefir, or yogurt. These are not the same.

How effective is it?

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS are as follows:

Possibly effective for...

  • Excessive crying in infants (colic). Giving infants B. lactis by mouth seems to help reduce crying from colic.
  • Constipation. Taking B. lactis by mouth seems to help relieve constipation.
  • A long-term disorder of the large intestines that causes stomach pain (irritable bowel syndrome or IBS). Taking B. lactis by mouth seems to help relieve symptoms of IBS. But it's not clear if taking it together with other probiotics helps.
  • Infection of the airways. Taking B. lactis by mouth might help prevent airway infections such as the common cold in otherwise healthy people. But it might not help people who have other serious health issues.

Possibly ineffective for...

  • Cavities. Taking B. lactis by mouth doesn't seem to prevent cavities in young children.
There is interest in using B. lactis for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.

Is it safe?

When taken by mouth: B. lactis is likely safe. It's been used safely alone and together with other probiotics for up to one month. Some people might experience gas and bloating from probiotics, but B. lactis seems to be well-tolerated.

Special precautions & warnings:

Pregnancy and breast-feeding: There isn't enough reliable information to know if B. lactis is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Children: B. lactis likely safe for healthy children when taken by mouth for up to 8 months. It might cause diarrhea in some kids.

Weakened immune system: Some probiotics have caused blood infections in a small number of people with weakened immune systems. If you have a weakened immune system, talk with your healthcare provider before taking B. lactis.

Are there interactions with medications?

Moderate
Be cautious with this combination.
Antibiotic drugs
B. lactis is a type of friendly bacteria. Antibiotics are used to reduce harmful bacteria in the body. Taking antibiotics along with B. lactis might reduce the effects of B. lactis. To avoid this interaction, take B. lactis products at least two hours before or after antibiotics.

Are there interactions with herbs and supplements?

There are no known interactions with herbs and supplements.

Are there interactions with foods?

There are no known interactions with foods.

How is it typically used?

In adults, B. lactis has most often been taken by mouth alone or together with other probiotics in doses of up to 12.5 billion colony-forming units (CFUs) daily, for up to 6 weeks. In children, B. lactis has most often been taken by mouth alone or together with other probiotics. Speak with a healthcare provider to find out what dose might be best for a specific condition.

Other names

B. Lactis, BB-12, BB12, Bifidobacterium Animalis DN-173 010, Bifidobacterium lactis, Bifidobacterium Regularis, Bifidus Regularis, Probiotic, Probiotique.

Methodology

To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.

References

  1. Wildt S, Munck LK, Vinter-Jensen L, et al. Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis. Inflamm Bowel Dis 2006;12:395-401. View abstract.
  2. Tavasoli S, Jalali S, Naji M, et al. Effect of a probiotic supplement containing Lactobacillus acidophilus and Bifidobacterium animalis Lactis on urine oxalate in calcium stone formers with hyperoxaluria: A randomized, placebo-controlled, double-blind and in-vitro trial. Urol J. 2021;19:179-188. View abstract.
  3. Companys J, Calderón-Pérez L, Pla-Pagà L, et al. Effects of enriched seafood sticks (heat-inactivated B. animalis subsp. lactis CECT 8145, inulin, omega-3) on cardiometabolic risk factors and gut microbiota in abdominally obese subjects: randomized controlled trial. Eur J Nutr 2022;61:3597-3611. View abstract.
  4. Grenov B, Namusoke H, Lanyero B, et al. Effect of probiotics on diarrhea in children with severe acute malnutrition: A randomized controlled study in Uganda. J Pediatr Gastroenterol Nutr 2017;64:396-403. View abstract.
  5. Gerasimov SV, Vasjuta VV, Myhovych OO, Bondarchuk LI. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. Am J Clin Dermatol 2010;11:351-61. View abstract.
  6. Mihatsch WA, Vossbeck S, Eikmanns B, Hoegel J, Pohlandt F. Effect of Bifidobacterium lactis on the incidence of nosocomial infections in very-low-birth-weight infants: a randomized controlled trial. Neonatology 2010;98:156-63. View abstract.
  7. Smith TJ, Rigassio-Radler D, Denmark R, Haley T, Touger-Decker R. Effect of Lactobacillus rhamnosus LGG® and Bifidobacterium animalis ssp. lactis BB-12® on health-related quality of life in college students affected by upper respiratory infections. Br J Nutr 2013;109:1999-2007. View abstract.
  8. de Almeida Silva Levi YL, Ribeiro MC, Silva PHF, et al. Effects of oral administration of Bifidobacterium animalis subsp. lactis HN019 on the treatment of plaque-induced generalized gingivitis. Clin Oral Investig 2023;27:387-398. View abstract.
  9. DI Pierro F, Lo Russo P, Danza ML, et al. Use of a probiotic mixture containing Bifidobacterium animalis subsp. lactis BB-12 and Enterococcus faecium L3 as prophylaxis to reduce the incidence of acute gastroenteritis and upper respiratory tract infections in children. Minerva Pediatr (Torino) 2021;73:222-229. View abstract.
  10. Dekker J, Quilter M, Qian H. Comparison of two probiotics in follow-on formula: Bifidobacterium animalis subsp. lactis HN019 reduced upper respiratory tract infections in Chinese infants. Benef Microbes 2022;13:341-353. View abstract.
  11. Tsai ML, Lin WY, Chen YT, et al. Adjuvant probiotic Bifidobacterium animalis subsp. lactis CP-9 improve phototherapeutic treatment outcomes in neonatal jaundice among full-term newborns: A randomized double-blind clinical study. Medicine (Baltimore) 2022;101:e31030. View abstract.
  12. Mäkelä SM, Forssten SD, Kailajärvi M, et al. Effects of Bifidobacterium animalis ssp. lactis 420 on gastrointestinal inflammation induced by a nonsteroidal anti-inflammatory drug: A randomized, placebo-controlled, double-blind clinical trial. Br J Clin Pharmacol 2021;87:4625-4635. View abstract.
  13. Liu H, Zhang K, Liu P, et al. Improvement effect of Bifidobacterium animalis subsp. lactis MH-02 in patients receiving resection of colorectal polyps: A randomized, double-blind, placebo-controlled trial. Front Immunol 2022;13:940500. View abstract.
  14. Mageswary MU, Ang XY, Lee BK, et al. Probiotic Bifidobacterium lactis Probio-M8 treated and prevented acute RTI, reduced antibiotic use and hospital stay in hospitalized young children: a randomized, double-blind, placebo-controlled study. Eur J Nutr 2022;61:1679-1691. View abstract.
  15. Miller LE, Ouwehand AC. Probiotic supplementation decreases intestinal transit time: meta-analysis of randomized controlled trials. World J Gastroenterol 2013;19:4718-25. View abstract.
  16. Airaksinen K, Yeung N, Lyra A, et al. The effect of a probiotic blend on gastrointestinal symptoms in constipated patients: a double blind, randomised, placebo controlled 2-week trial. Benef Microbes 2019;10:617-627. View abstract.
  17. Eskandarzadeh S, Effatpanah M, Khosravi-Darani K, et al. Efficacy of a multispecies probiotic as adjunctive therapy in generalized anxiety disorder: a double blind, randomized, placebo-controlled trial. Nutr Neurosci 2021;24:102-108. View abstract.
  18. Tonucci LB, Olbrich Dos Santos KM, Licursi de Oliveira L, Rocha Ribeiro SM, Duarte Martino HS. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clin Nutr 2017;36:85-92. View abstract.
  19. Martoni CJ, Evans M, Chow CT, Chan LS, Leyer G. Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: A randomized controlled trial. J Dig Dis 2019;20:435-446. View abstract.
  20. Lukasik J, Dierikx T, Besseling-van der Vaart I, de Meij T, Szajewska H; Multispecies probiotic in AAD study group. Multispecies probiotic for the prevention of antibiotic-associated diarrhea in children: A randomized clinical trial. JAMA Pediatr 2022;176:860-866. View abstract.
  21. van der Schoot A, Helander C, Whelan K, Dimidi E. Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr 2022;41:2759-2777. View abstract.
  22. Saros L, Vahlberg T, Koivuniemi E, et al. Fish Oil And/Or Probiotics Intervention in Overweight/Obese Pregnant Women and Overweight Risk in 24-Month-Old Children. J Pediatr Gastroenterol Nutr 2023;76:218-226. View abstract.
  23. Li Z, Zhu G, Li C, Lai H, Liu X, Zhang L. Which probiotic is the most effective for treating acute diarrhea in children? A Bayesian network meta-analysis of randomized controlled trials. Nutrients 2021;13:4319. View abstract.
  24. Goodman C, Keating G, Georgousopoulou E, Hespe C, Levett K. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open 2021;11:e043054. View abstract.
  25. Hu D, Zhong T, Dai Q. Clinical efficacy of probiotics as an adjunctive therapy to scaling and root planing in the management of periodontitis: A systematic review and meta-analysis of randomized controlled trials. J Evid Based Dent Pract 2021;21:101547. View abstract.
  26. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55:2234-2248. View abstract.
  27. Hagen PC, Skelley JW. Efficacy of Bifidobacterium species in prevention of necrotizing enterocolitis in very-low birth weight infants. A Systematic Review. J Pediatr Pharmacol Ther. 2019;24:10-15. View abstract.
  28. Wang L, Guo MJ, Gao Q, Yang JF, Yang L, Pang XL, Jiang XJ. The effects of probiotics on total cholesterol: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97:e9679. View abstract.
  29. Ustundag GH, Altuntas H, Soysal YD, Kokturk F. The effects of synbiotic "Bifidobacterium lactis B94 plus Inulin" addition on standard triple therapy of Helicobacter pylori eradication in children. Can J Gastroenterol Hepatol. 2017;2017:8130596. View abstract.
  30. Çekin AH, Sahintürk Y, Akbay Harmandar F, Uyar S, Yolcular BO, Çekin Y. Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. Turk J Gastroenterol. 2017;28:3-11. View abstract.
  31. Taipale T, Pienihäkkinen K, Alanen P, Jokela J, Söderling E. Administration of Bifidobacterium animalis subsp. lactis BB-12 in early childhood: a post-trial effect on caries occurrence at four years of age. Caries Res. 2013;47:364-72. View abstract.
  32. Nocerino R, De Filippis F, Cecere G, et al. The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12® in infant colic: A randomised, double blind, placebo-controlled trial. Aliment Pharmacol Ther. 2020;51:110-120. View abstract.
  33. Merenstein D, Fraser CM, Roberts RF, et al. Bifidobacterium animalis subsp. lactis BB-12 protects against antibiotic-induced functional and compositional changes in human fecal microbiome. Nutrients 2021;13:2814. View abstract.
  34. Kong XJ, Wan G, Tian R, et al. The effects of probiotic supplementation on anthropometric growth and gut microbiota composition in patients with Prader-Willi syndrome: A randomized double-blinded placebo-controlled trial. Front Nutr 2021;8:587974. View abstract.
  35. Hao S, Wang J, Wang Y. Effectiveness and safety of Bifidobacterium in preventing dental caries: a systematic review and meta-analysis. Acta Odontol Scand 2021;79:613-622. View abstract.
  36. Chen K, Zhang G, Xie H, et al. Efficacy of Bifidobacterium animalis subsp. lactis, BB-12(®) on infant colic - a randomised, double-blinded, placebo-controlled study. Benef Microbes 2021;12:531-540. View abstract.
  37. Anania C, Di Marino VP, Olivero F, et al. Treatment with a probiotic mixture containing Bifidobacterium animalis Subsp. Lactis BB12 and Enterococcus faecium L3 for the prevention of allergic rhinitis symptoms in children: A randomized controlled trial. Nutrients 2021;13:1315. View abstract.
  38. Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial. Nutrients. 2020;12:363. View abstract.
  39. Alanzi A, Honkala S, Honkala E, Varghese A, Tolvanen M, Söderling E. Effect of Lactobacillus rhamnosus and Bifidobacterium lactis on gingival health, dental plaque, and periodontopathogens in adolescents: a randomised placebo-controlled clinical trial. Benef Microbes. 2018;9:593-602. View abstract.
  40. Toiviainen A, Jalasvuori H, Lahti E, et al. Impact of orally administered lozenges with Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12 on the number of salivary mutans streptococci, amount of plaque, gingival inflammation and the oral microbiome in healthy adults. Clin Oral Investig. 2015;19:77-83. View abstract.
  41. Navarro-López V, Ramírez-Boscá A, Ramón-Vidal D, et al. Effect of oral administration of a mixture of probiotic strains on SCORAD index and use of topical steroids in young patients with moderate atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2018;154:37-43. View abstract.
  42. Tsilika M, Thoma G, Aidoni Z, et al. A four-probiotic preparation for ventilator-associated pneumonia in multi-trauma patients: results of a randomized clinical trial. Int J Antimicrob Agents 2022;59:106471. View abstract.
  43. Castro-Herrera VM, Fisk HL, Wootton M, et al. Combination of the probiotics Lacticaseibacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis, BB-12 has limited effect on biomarkers of immunity and inflammation in older people resident in care homes: Results from the probiotics to reduce infections in care home residents randomized, controlled trial. Front Immunol 2021;12:643321. View abstract.
  44. Groele L, Szajewska H, Szalecki M, et al. Lack of effect of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: a randomised controlled trial. BMJ Open Diabetes Res Care 2021;9:e001523. View abstract.
  45. Kim MC, Lee S, Park JK, et al. Effects of ID-HWS1000 on the perception of bowel activity and microbiome in subjects with functional constipation: A randomized, double-blind placebo-controlled study. J Med Food 2021;24:883-893. View abstract.
  46. Skrzydlo-Radomanska B, Prozorow-Król B, Cichoz-Lach H, et al. The effectiveness and safety of multi-strain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: A randomized controlled study. Nutrients 2021;13:756. View abstract.
  47. Sun M, Luo J, Liu H, Xi Y, Lin Q. Can mixed strains of Lactobacillus and Bifidobacterium reduce eczema in infants under three years of age? A meta-analysis. Nutrients 2021;13:1461. View abstract.
  48. Moludi J, Khedmatgozar H, Saiedi S, Razmi H, Alizadeh M, Ebrahimi B. Probiotic supplementation improves clinical outcomes and quality of life indicators in patients with plaque psoriasis: A randomized double-blind clinical trial. Clin Nutr ESPEN 2021;46:33-39. View abstract.
  49. Hulkkonen P, Kataja EL, Vahlberg T, et al. The efficacy of probiotics and/or n-3 long-chain polyunsaturated fatty acids intervention on maternal prenatal and postnatal depressive and anxiety symptoms among overweight and obese women. J Affect Disord 2021;289:21-30. View abstract.
  50. Liu AT, Chen S, Jena PK, Sheng L, Hu Y, Wan YY. Probiotics improve gastrointestinal function and life quality in pregnancy. Nutrients 2021;13:3931. View abstract.
  51. Garaiova I, Paduchová Z, Nagyová Z, et al. Probiotics with vitamin C for the prevention of upper respiratory tract symptoms in children aged 3-10 years: randomised controlled trial. Benef Microbes 2021;12:431-440. View abstract.
  52. Pedret A, Valls RM, Calderón-Pérez L, et al. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond). 2019;43:1863-1868. View abstract.
  53. Davidson SJ, Barrett HL, Price SA, Callaway LK, Dekker Nitert M. Probiotics for preventing gestational diabetes. Cochrane Database Syst Rev. 2021;4:CD009951. View abstract.
  54. Morvaridzadeh M, Nachvak SM, Mohammadi R, et al. Probiotic yogurt fortified with vitamin D can improve glycemic status in non-alcoholic fatty liver disease patients: a randomized clinical trial. Clin Nutr Res. 2021;10:36-47. View abstract.
  55. Sharif S, Meader N, Oddie SJ, Rojas-Reyes MX, McGuire W. Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants. Cochrane Database Syst Rev. 2020;10:CD005496. View abstract.
  56. Invernici MM, Salvador SL, Silva PHF, et al. Effects of Bifidobacterium probiotic on the treatment of chronic periodontitis: A randomized clinical trial. J Clin Periodontol. 2018;45:1198-1210. View abstract.
  57. Invernici MM, Furlaneto FAC, Salvador SL, et al. Bifidobacterium animalis subsp lactis HN019 presents antimicrobial potential against periodontopathogens and modulates the immunological response of oral mucosa in periodontitis patients. PLoS One. 2020;15:e0238425. View abstract.
  58. Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr. 2017;64:413-417. View abstract.
  59. Bernini LJ, Simão AN, Alfieri DF, et al. Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. Nutrition. 2016;32:716-9. View abstract.
  60. Amat-Bou M, Garcia-Ribera S, Climent E, et al. Effects of Bifidobacterium animalis Subsp. lactis (BPL1) supplementation in children and adolescents with prader-willi syndrome: A randomized crossover trial. Nutrients. 2020;12:3123. View abstract.
  61. Cheng B, Zeng X, Liu S, Zou J, Wang Y. The efficacy of probiotics in management of recurrent aphthous stomatitis: a systematic review and meta-analysis. Scientific reports. 2020;10:1-1.
  62. Pellonperä O, Mokkala K, Houttu N, et al. Efficacy of fish oil and/or probiotic intervention on the incidence of gestational diabetes mellitus in an at-risk group of overweight and obese women: A randomized, placebo-controlled, double-blind clinical trial. Diabetes Care. 2019;42:1009-1017. View abstract.
  63. Michael DR, Jack AA, Masetti G, et al. A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being. Sci Rep. 2020;10:4183. View abstract.
  64. Czajeczny D, Kabzińska K, Wójciak RW. Does probiotic supplementation aid weight loss? A randomized, single-blind, placebo-controlled study with Bifidobacterium lactis BS01 and Lactobacillus acidophilus LA02 supplementation. Eat Weight Disord. 2020. View abstract.
  65. Jiao X, Fu MD, Wang YY, Xue J, Zhang Y. Bifidobacterium and Lactobacillus for preventing necrotizing enterocolitis in very-low-birth-weight preterm infants: a systematic review and meta-analysis. World J Pediatr. 2020;16:135-142. View abstract.
  66. Sadeghi-Bojd S, Naghshizadian R, Mazaheri M, Ghane Sharbaf F, Assadi F. Efficacy of probiotic prophylaxis after the first febrile urinary tract infection in children with normal urinary tracts. J Pediatric Infect Dis Soc. 2020;9:305-310. View abstract.
  67. Butler CC, Lau M, Gillespie D, et al. Effect of probiotic use on antibiotic administration among care home residents: A randomized clinical trial. JAMA. 2020;324:47-56. View abstract.
  68. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27:175-178. View abstract.
  69. Dimidi E, Zdanaviciene A, Christodoulides S, et al. Randomised clinical trial: Bifidobacterium lactis NCC2818 probiotic vs placebo, and impact on gut transit time, symptoms, and gut microbiology in chronic constipation. Aliment Pharmacol Ther. 2019;49:251-264. View abstract.
  70. Slykerman RF, Kang J, Van Zyl N, et al. Effect of early probiotic supplementation on childhood cognition, behaviour and mood a randomised, placebo-controlled trial. Acta Paediatr. 2018;107:2172-2178. View abstract.
  71. Schmidt RM, Pilmann Laursen R, Bruun S, et al. Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial. Pediatr Allergy Immunol. 2019;30:335-340. View abstract.
  72. Linn YH, Thu KK, Win NHH. Effect of Probiotics for the Prevention of Acute Radiation-Induced Diarrhoea Among Cervical Cancer Patients: a Randomized Double-Blind Placebo-Controlled Study. Probiotics Antimicrob Proteins. 2019;11:638-647. View abstract.
  73. Callaway LK, McIntyre HD, Barrett HL, et al. Probiotics for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Women: Findings From the SPRING Double-Blind Randomized Controlled Trial. Diabetes Care. 2019;42:364-371. View abstract.
  74. Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. 2018;9:236-251. View abstract.
  75. Guardamagna O, Amaretti A, Puddu PE, et al. Bifidobacteria supplementation: effects on plasma lipid profiles in dyslipidemic children. Nutrition. 2014;30(7-8):831-6. View abstract.
  76. Kuru BE, Laleman I, Yalnizoglu T, Kuru L, Teughels W. The influence of a Bifidobacterium animalis probiotic on gingival health: A randomized controlled clinical trial. J Periodontol. 2017;88:1115-1123. View abstract.
  77. Guarino A, Ashkenazi S, Gendrel D, Lo Vecchio A, Shamir R, Szajewska H; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; European Society for Pediatric Infectious Diseases. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr. 2014 Jul;59:132-52. View abstract.
  78. Gerasimov SV, Ivantsiv VA, Bobryk LM, et al. Role of short-term use of L. acidophilus DDS-1 and B. lactis UABLA-12 in acute respiratory infections in children: a randomized controlled trial. Eur J Clin Nutr. 2016 Apr;70:463-9. View abstract.
  79. Dickerson F, Adamos M, Katsafanas E, et al. Adjunctive probiotic microorganisms to prevent rehospitalization in patients with acute mania: A randomized controlled trial. Bipolar Disord. 2018 Apr 25. View abstract.
  80. Simpson MR, Dotterud CK, Storrø O, Johnsen R, Øien T. Perinatal probiotic supplementation in the prevention of allergy related disease: 6 year follow up of a randomised controlled trial. BMC Dermatol. 2015;15:13. View abstract.
  81. Dolatkhah N, Hajifaraji M, Abbasalizadeh F, Aghamohammadzadeh N, Mehrabi Y, Abbasi MM. Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial. J Health Popul Nutr. 2015;33:25. View abstract.
  82. Topcuoglu S, Gursoy T, Ovali F, Serce O, Karatekin G. A new risk factor for neonatal vancomycin-resistant Enterococcus colonisation: bacterial probiotics. J Matern Fetal Neonatal Med. 2015;28:1491-4. View abstract.
  83. Pinto GS, Cenci MS, Azevedo MS, Epifanio M, Jones MH. Effect of yogurt containing Bifidobacterium animalis subsp . lactis DN-173010 probiotic on dental plaque and saliva in orthodontic patients. Caries Res. 2014;48:63-8. View abstract.
  84. Koning CJ, Jonkers DM, Stobberingh EE, et al. The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin. Am J Gastroenterol 2008;103:178-89. View abstract.
  85. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017 Oct 19. [Epub ahead of print]. View abstract.
  86. Hojsak I, Mocic Pavic A, Kos T, Dumancic J, Kolacek S. Bifidobacterium animalis subsp. lactis in prevention of common infections in healthy children attending day care centers - Randomized, double blind, placebo-controlled study. Clin Nutr 2016;35:587-91. View abstract.
  87. Taipale TJ, Pienihäkkinen K, Isolauri E, Jokela JT, Söderling EM. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in early childhood. Pediatr Res. 2016;79(1-1):65-9. View abstract.
  88. Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27-37. View abstract.
  89. Stenman LK, Lehtinen MJ, Meland N, et al. Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial. EBioMedicine 2016;13:190-200. View abstract.
  90. Han K, Wang J, Seo JG, Kim H. Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial. J Gastroenterol. 2017;52:432-443. View abstract.
  91. Chang HY, Chen JH, Chang JH, Lin HC, Lin CY, Peng CC. Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: An updated meta-analysis. PLoS One. 2017;12:e0171579. View abstract.
  92. Bastürk A, Artan R, Yilmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial. Turk J Gastroenterol 2016;27:439-43. View abstract.
  93. Blaabjerg S, Artzi DM, Aabenhus R. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2017;6. View abstract.
  94. Al Faleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2014;:CD005496. View abstract.
  95. Dimidi E, Christodoulides S, Fragkos KC, Scott SM, Whelan K. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100:1075-84. View abstract.
  96. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 2011;5:115-21. View abstract.
  97. Søndergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol 2011;46:663-72. View abstract.
  98. Simrén M, Ohman L, Olsson J, et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - a randomized, double-blind, controlled study. Aliment Pharmacol Ther 2010;31:218-27. View abstract.
  99. Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015;:CD004827. View abstract.
  100. O'Callaghan A, van Sinderen D. Bifidobacteria and Their Role as Members of the Human Gut Microbiota. Front Microbiol. 2016 Jun 15;7:925. View abstract.
  101. Hojsak I, Tokic Pivac V, Mocic Pavic A, Pasini AM, Kolacek S. Bifidobacterium animalis subsp. lactis fails to prevent common infections in hospitalized children: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr. 2015 Mar;101:680-4. View abstract.
  102. Eskesen D, Jespersen L, Michelsen B, Whorwell PJ, Müller-Lissner S, Morberg CM. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled,parallel-group trial. Br J Nutr. 2015 Nov 28;114:1638-46. View abstract.
  103. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB, Mack D. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013 Oct 12;382:1249-57. View abstract.
  104. Roberfroid MB. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr. 2000;71(6 Suppl):1682S-7S; discussion 1688S-90S. View abstract.
  105. Magro DO, de Oliveira LM, Bernasconi I, Ruela Mde S, Credidio L, Barcelos IK, Leal RF, Ayrizono Mde L, Fagundes JJ, Teixeira Lde B, Ouwehand AC, Coy CS. Effect of yogurt containing polydextrose, Lactobacillus acidophilus NCFM and Bifidobacterium lactis HN019: a randomized, double-blind, controlled study in chronic constipation. Nutr J. 2014 24;13:75. View abstract.
  106. Gore C, Custovic A, Tannock GW, Munro K, Kerry G, Johnson K, Peterson C, Morris J, Chaloner C, Murray CS, Woodcock A. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. Clin Exp Allergy 2012;42:112-22. View abstract.
  107. Chatterjee S, Kar P, Das T, Ray S, Gangulyt S, Rajendiran C, Mitra M. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J Assoc Physicians India 2013;61:708-12. View abstract.
  108. Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013;48:1127-35. View abstract.
  109. Allen SJ, Jordan S, Storey M, Thornton CA, Gravenor MB, Garaiova I, Plummer SF, Wang D, Morgan G. Probiotics in the prevention of eczema: a randomised controlled trial. Arch Dis Child 2014;99:1014-9. View abstract.
  110. Das RR.Singh M, Shafiq N. Probiotics in Treatment of Allergic Rhinitis. World Allergy Organization Journal 2010;3:239-244.
  111. Seki M, Igarashi T Fukuda Y Simamura S Kaswashima T Ogasa K. The effect of Bifidobacterium cultured milk on the "regularity" among an aged group. Nutr Foodstuff 1978;31:379-387.
  112. Kageyama T, Nakano Y Tomoda T. Comparative Study on Oral Administration of Some Bifidobacterium Preparations. Medicine and Biology(Japan) 1987;115:65-68.
  113. Kageyama T, Tomoda T Nakano Y. The Effect of Bifidobacterium Administration in Patients with Leukemia. Bifidobacteria Microflora. 1984;3:29-33.
  114. Ballongue J, Grill J Baratte-Euloge P. Action sur la flore intestinale de laits fermentés au Bifidobacterium. Lait 1993;73:249-256.
  115. Ogata T, Kingaku M Yaeshima T Teraguchi S Fukuwatari Y Ishibashi N Hayasawa H Fujisawa T Lino H. Effect of Bifidobacterium longum BB536 yogurt administration on the intestinal environment of healthy adults. Microb Ecol Health Dis 1999;11:41-46.
  116. Tomoda T, Nakano Y Kageyama T. Variation in Small Groups of Constant Intestinal Flora during Administration of Anticancer or Immunosuppressive Drugs. Medicine and Biology(Japan) 1981;103:45-49.
  117. Tomoda T, Nakano Y Kageyama T. Intestinal Candida Overgrowth and Candida Infection in Patients with Leukemia: Effect of Bifidobacterium Administration. Bifidobacteria Microflora 1988;7:71-74.
  118. Araya-Kojima Tomoko, Yaeshima Tomoko Ishibashi Norio Shimamura Seiichi Hayasawa Hirotoshi. Inhibitory Effects of Bifidobacterium longum BB536 on Harmful Intestinal Bacteria. Bifidobacteria Microflora 1995;14:59-66.
  119. Igarashi M, Iiyama Y Kato R Tomita M Asami N Ezawa I. Effect of Bifidobacterium longum and lactulose on the strength of bone in ovariectomized osteoporosis model rates. Bifidus 1994;7:139-147.
  120. Yaeshima T, Takahashi S Ota S Nakagawa K Ishibashi N Hiramatsu A Ohashi T Hayasawa H Iino H. Effect of sweet yogurt containing Bifidobacterium longum BB536 on defecation frequency and fecal characteristics of healthy adults: A comparison with sweet standard yogurt. Kenko Eiyo Shokuhin Kenkyu 1998;1(3/4):29-34.
  121. Yaeshima T, Takahashi S Matsumoto N Ishibashi N Hayasawa H Lino H. Effect of yogurt containing Bifidobacterium longum BB536 on the intestinal environment, fecal characteristics and defecation frequency: A comparison with standard yogurt. Biosci Microflora 1997;16:73-77.
  122. Xiao J, Kondol S Odamaki T Miyaji K Yaeshima T Iwatsuki K Togashi H Benno Y. Effect of yogurt containing Bifidobacterium longum BB 536 on the defecation frequency and fecal characteristics of healthy adults: A double-blind cross over study. Japanese Journal of Lactic Acid Bacteria 2007;18:31-36.
  123. Yaeshima T, Takahashi S Ogura A Konno T Iwatsuki K Ishibashi N Hayasawa H. Effect of Non-fermented Milk Containing Bifidobacterium longum BB536 on the Defecation Frequency and Fecal Characteristics in Healthy Adults. Journal of Nutrition Food 2001;4:1-6.
  124. Ogata T, Nakamura T Anjitsu K Yaeshima T Takahashi S Fukuwatari Y Ishibashi N Hayasawa H Fujisawa T Iino H. Effect of Bifidobacterium longum BB536 administration on the intestinal environment, defecation frequency and fecal characteristics of human volunteers. Biosci Microflora 1997;16:53-58.
  125. Iwabuchi N, Hiruta N Kanetada S Yaeshima T Iwatsuki K Yasui H. Effects of Intranasal Administration of Bifidobacterium longum BB536 on Mucosal Immune System in Respiratory Tract and Influenza Virus Infection in Mice. Milk Science 2009;38:129-133.
  126. Yamazaki, S., Machii, K., Tsuyuki, S., Momose, H., Kawashima, T., and Ueda, K. Immunological responses to monoassociated Bifidobacterium longum and their relation to prevention of bacterial invasion. Immunology 1985;56:43-50. View abstract.
  127. Kondo, J., Xiao, J. Z., Shirahata, A., Baba, M., Abe, A., Ogawa, K., and Shimoda, T. Modulatory effects of Bifidobacterium longum BB536 on defecation in elderly patients receiving enteral feeding. World J Gastroenterol 4-14-2013;19:2162-2170. View abstract.
  128. Akatsu, H., Iwabuchi, N., Xiao, J. Z., Matsuyama, Z., Kurihara, R., Okuda, K., Yamamoto, T., and Maruyama, M. Clinical Effects of Probiotic Bifidobacterium longum BB536 on Immune Function and Intestinal Microbiota in Elderly Patients Receiving Enteral Tube Feeding. JPEN J Parenter Enteral Nutr 11-27-2012; View abstract.
  129. Odamaki, T., Sugahara, H., Yonezawa, S., Yaeshima, T., Iwatsuki, K., Tanabe, S., Tominaga, T., Togashi, H., Benno, Y., and Xiao, J. Z. Effect of the oral intake of yogurt containing Bifidobacterium longum BB536 on the cell numbers of enterotoxigenic Bacteroides fragilis in microbiota. Anaerobe. 2012;18:14-18. View abstract.
  130. Iwabuchi, N., Xiao, J. Z., Yaeshima, T., and Iwatsuki, K. Oral administration of Bifidobacterium longum ameliorates influenza virus infection in mice. Biol.Pharm.Bull. 2011;34:1352-1355. View abstract.
  131. Firmansyah, A., Dwipoerwantoro, P. G., Kadim, M., Alatas, S., Conus, N., Lestarina, L., Bouisset, F., and Steenhout, P. Improved growth of toddlers fed a milk containing synbiotics. Asia Pac.J Clin.Nutr. 2011;20:69-76. View abstract.
  132. Tang, M. L., Lahtinen, S. J., and Boyle, R. J. Probiotics and prebiotics: clinical effects in allergic disease. Curr.Opin.Pediatr. 2010;22:626-634. View abstract.
  133. Namba, K., Hatano, M., Yaeshima, T., Takase, M., and Suzuki, K. Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cell-mediated immunity in the elderly. Biosci.Biotechnol.Biochem. 2010;74:939-945. View abstract.
  134. Gianotti, L., Morelli, L., Galbiati, F., Rocchetti, S., Coppola, S., Beneduce, A., Gilardini, C., Zonenschain, D., Nespoli, A., and Braga, M. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol. 1-14-2010;16:167-175. View abstract.
  135. Andrade, S. and Borges, N. Effect of fermented milk containing Lactobacillus acidophilus and Bifidobacterium longum on plasma lipids of women with normal or moderately elevated cholesterol. J.Dairy Res. 2009;76:469-474. View abstract.
  136. Rouge, C., Piloquet, H., Butel, M. J., Berger, B., Rochat, F., Ferraris, L., Des, Robert C., Legrand, A., de la Cochetiere, M. F., N'Guyen, J. M., Vodovar, M., Voyer, M., Darmaun, D., and Roze, J. C. Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. Am.J Clin.Nutr. 2009;89:1828-1835. View abstract.
  137. Iwabuchi, N., Takahashi, N., Xiao, J. Z., Yonezawa, S., Yaeshima, T., Iwatsuki, K., and Hachimura, S. Suppressive effects of Bifidobacterium longum on the production of Th2-attracting chemokines induced with T cell-antigen-presenting cell interactions. FEMS Immunol.Med.Microbiol. 2009;55:324-334. View abstract.
  138. Takeda, Y., Nakase, H., Namba, K., Inoue, S., Ueno, S., Uza, N., and Chiba, T. Upregulation of T-bet and tight junction molecules by Bifidobactrium longum improves colonic inflammation of ulcerative colitis. Inflamm.Bowel.Dis. 2009;15:1617-1618. View abstract.
  139. Soh, S. E., Aw, M., Gerez, I., Chong, Y. S., Rauff, M., Ng, Y. P., Wong, H. B., Pai, N., Lee, B. W., and Shek, L. P. Probiotic supplementation in the first 6 months of life in at risk Asian infants--effects on eczema and atopic sensitization at the age of 1 year. Clin.Exp.Allergy 2009;39:571-578. View abstract.
  140. Odamaki, T., Xiao, J. Z., Sakamoto, M., Kondo, S., Yaeshima, T., Iwatsuki, K., Togashi, H., Enomoto, T., and Benno, Y. Distribution of different species of the Bacteroides fragilis group in individuals with Japanese cedar pollinosis. Appl.Environ.Microbiol. 2008;74:6814-6817. View abstract.
  141. del Giudice, M. M. and Brunese, F. P. Probiotics, prebiotics, and allergy in children: what's new in the last year? J Clin.Gastroenterol. 2008;42 Suppl 3 Pt 2:S205-S208. View abstract.
  142. Chouraqui, J. P., Grathwohl, D., Labaune, J. M., Hascoet, J. M., de, Montgolfier, I, Leclaire, M., Giarre, M., and Steenhout, P. Assessment of the safety, tolerance, and protective effect against diarrhea of infant formulas containing mixtures of probiotics or probiotics and prebiotics in a randomized controlled trial. Am.J Clin.Nutr. 2008;87:1365-1373. View abstract.
  143. Odamaki, T., Xiao, J. Z., Iwabuchi, N., Sakamoto, M., Takahashi, N., Kondo, S., Miyaji, K., Iwatsuki, K., Togashi, H., Enomoto, T., and Benno, Y. Influence of Bifidobacterium longum BB536 intake on faecal microbiota in individuals with Japanese cedar pollinosis during the pollen season. J Med.Microbiol. 2007;56(Pt 10):1301-1308. View abstract.
  144. Iwabuchi, N., Takahashi, N., Xiao, J. Z., Miyaji, K., and Iwatsuki, K. In vitro Th1 cytokine-independent Th2 suppressive effects of bifidobacteria. Microbiol.Immunol. 2007;51:649-660. View abstract.
  145. Xiao, J. Z., Kondo, S., Takahashi, N., Odamaki, T., Iwabuchi, N., Miyaji, K., Iwatsuki, K., and Enomoto, T. Changes in plasma TARC levels during Japanese cedar pollen season and relationships with symptom development. Int.Arch.Allergy Immunol. 2007;144:123-127. View abstract.
  146. Odamaki, T., Xiao, J. Z., Iwabuchi, N., Sakamoto, M., Takahashi, N., Kondo, S., Iwatsuki, K., Kokubo, S., Togashi, H., Enomoto, T., and Benno, Y. Fluctuation of fecal microbiota in individuals with Japanese cedar pollinosis during the pollen season and influence of probiotic intake. J Investig.Allergol.Clin.Immunol. 2007;17:92-100. View abstract.
  147. Xiao, J. Z., Kondo, S., Yanagisawa, N., Miyaji, K., Enomoto, K., Sakoda, T., Iwatsuki, K., and Enomoto, T. Clinical efficacy of probiotic Bifidobacterium longum for the treatment of symptoms of Japanese cedar pollen allergy in subjects evaluated in an environmental exposure unit. Allergol.Int. 2007;56:67-75. View abstract.
  148. Puccio, G., Cajozzo, C., Meli, F., Rochat, F., Grathwohl, D., and Steenhout, P. Clinical evaluation of a new starter formula for infants containing live Bifidobacterium longum BL999 and prebiotics. Nutrition 2007;23:1-8. View abstract.
  149. Xiao, J. Z., Kondo, S., Yanagisawa, N., Takahashi, N., Odamaki, T., Iwabuchi, N., Miyaji, K., Iwatsuki, K., Togashi, H., Enomoto, K., and Enomoto, T. Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo-controlled trial. Clin.Exp.Allergy 2006;36:1425-1435. View abstract.
  150. Xiao, J. Z., Kondo, S., Yanagisawa, N., Takahashi, N., Odamaki, T., Iwabuchi, N., Iwatsuki, K., Kokubo, S., Togashi, H., Enomoto, K., and Enomoto, T. Effect of probiotic Bifidobacterium longum BB536 [corrected] in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season. A randomized double-blind, placebo-controlled trial. J Investig.Allergol.Clin.Immunol. 2006;16:86-93. View abstract.
  151. Bennet, R., Nord, C. E., and Zetterstrom, R. Transient colonization of the gut of newborn infants by orally administered bifidobacteria and lactobacilli. Acta Paediatr. 1992;81:784-787. View abstract.
  152. Orrhage, K., Sjostedt, S., and Nord, C. E. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob.Chemother. 2000;46:603-612. View abstract.
  153. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74:336-42. View abstract.
  154. AlFaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD005496. DOI: 10.1002/14651858.CD005496.pub3. View abstract.
  155. Tabbers MM, Milliano I, Roseboom MG, Benninga MA. Is Bifidobacterium breve effective in the treatment of childhood constipation? Results from a pilot study. Nutr J 2011;10:19. View abstract.
  156. Leyer GJ, Li S, Mubasher ME, et al. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics 2009;124:e172-e179. View abstract.
  157. Miele E, Pascarella F, Giannetti E. et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437-43. View abstract.
  158. Kuhbacher T, Ott SJ, Helwig U, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006;55:833-41. View abstract.
  159. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-46. View abstract.
  160. Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004;10:PI126-31. View abstract.
  161. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004;20:1133-41. View abstract.
  162. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51. View abstract.
  163. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56-63. View abstract.
  164. Rastall RA. Bacteria in the gut: friends and foes and how to alter the balance. J Nutr 2004;134:2022S-2026S. View abstract.
  165. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14. View abstract.
  166. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002;97:2744-9. View abstract.
  167. Sullivan A, Barkholt L, Nord CE. Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine. J Antimicrob Chemother 2003;52:308-11. View abstract.
  168. Roberfroid MB. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr 2000;71:1682S-7S. View abstract.
  169. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60. View abstract.
  170. Goldin BR. Health Benefits of probiotics. Br J Nutr 1998;80:S203-7. View abstract.
  171. Kalima P, Masterton RG, Roddie PH, et al. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996;32:165-7. View abstract.
  172. Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in southern Finland 1989-1992. Clin Infect Dis 1996;22:564-6. View abstract.
  173. Lewis SJ, Freedman AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998;12:807-22. View abstract.
  174. Meydani SN, Ha WK. Immunologic effects of yogurt. Am J Clin Nutr 2000;71:861-72. View abstract.
  175. Isolauri E, Arvola T, Sutas Y, et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000;30:1604-10. View abstract.
  176. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-8. View abstract.
  177. Phuapradit P, Varavithya W, Vathanophas K, et al. Reduction of rotavirus infection in children receiving bifidobacteria-supplemented formula. J Med Assoc Thai 1999;82:S43-8. View abstract.
  178. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  179. Chen RM, Wu JJ, Lee SC, et al. Increase of intestinal Bifidobacterium and suppression of coliform bacteria with short-term yogurt ingestion. J Dairy Sci 1999:82:2308-14. View abstract.
  180. Ha GY, Yang CH, Kim H, Chong Y. Case of sepsis caused by Bifidobacterium longum. J Clin Microbiol 1999;37:1227-8. View abstract.
  181. Hirayama K, Rafter J. The role of probiotic bacteria in cancer prevention. Microbes Infect 2000;2:681-6. View abstract.
  182. Macfarlane GT, Cummings JH. Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? BMJ 1999;318:999-1003. View abstract.
  183. Chiang BL, Sheih YH, Wang LH, et al. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses. Eur J Clin Nutr 2000;54:849-55. View abstract.
  184. Lievin V, Peiffer I, Hudault S, et al. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 2000;47:646-52. View abstract.
  185. Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr 2000;54:263-7. View abstract.
  186. Saavedra JM, et al. Feeding of bifidobacterium bifidum and streptococcus thermophilus to infants in hospital for prevention of diarrhea and shedding of rotavirus. Lancet 1994;344:1046-9. View abstract.
Last reviewed - 08/23/2023